Castle Biosciences Inc.

34.21-0.1100-0.32%Vol 416.88K1Y Perf -45.77%
Aug 11th, 2022 16:00 DELAYED
BID31.05 ASK37.00
Open34.71 Previous Close34.32
Pre-Market- After-Market35.00
 - -  0.79 2.31%
Target Price
46.00 
Analyst Rating
Strong Buy 1.00
Potential %
34.46 
Finscreener Ranking
★★★★+ —    58.12
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
★★★★     56.08
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★+     55.90
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
29.57 
Earnings Rating
Market Cap899.59M 
Earnings Date
8th Aug 2022
Alpha0.01 Standard Deviation0.19
Beta1.04 

Today's Price Range

33.8336.10

52W Range

15.5878.59

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
11.94%
1 Month
32.49%
3 Months
80.34%
6 Months
-21.28%
1 Year
-45.77%
3 Years
64.79%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CSTL34.21-0.1100-0.32
AAPL168.49-0.7500-0.44
GOOG119.82-0.8300-0.69
MSFT287.02-2.1400-0.74
XOM93.192.62002.89
WFC45.250.92002.08
JNJ167.14-3.5300-2.07
FB196.640.99000.51
GE78.901.76002.28
JPM120.141.75001.48
 
ProfitabilityValueIndustryS&P 500US Markets
80.90
-61.40
-55.90
-36.90
-56.85
RevenueValueIndustryS&P 500US Markets
75.37M
2.87
40.78
-
Earnings HistoryEstimateReportedSurprise %
Q02 2022-0.58-0.0689.66
Q01 2022-0.67-0.80-19.40
Q04 2021-0.43-0.2541.86
Q03 2021-0.35-0.47-34.29
Q02 2021-0.29-0.34-17.24
Q01 2021-0.22-0.1722.73
Q04 2020-0.11-0.16-45.45
Q03 2020-0.06-0.23-283.33
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date-
Estimated EPS Next Report-0.57
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume416.88K
Shares Outstanding26.30K
Shares Float21.90M
Trades Count8.03K
Dollar Volume14.59M
Avg. Volume304.39K
Avg. Weekly Volume365.29K
Avg. Monthly Volume233.59K
Avg. Quarterly Volume314.29K

Castle Biosciences Inc. (NASDAQ: CSTL) stock closed at 34.21 per share at the end of the most recent trading day (a -0.32% change compared to the prior day closing price) with a volume of 416.88K shares and market capitalization of 899.59M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 135 people. Castle Biosciences Inc. CEO is Derek J. Maetzold.

The one-year performance of Castle Biosciences Inc. stock is -45.77%, while year-to-date (YTD) performance is -20.2%. CSTL stock has a five-year performance of %. Its 52-week range is between 15.58 and 78.585, which gives CSTL stock a 52-week price range ratio of 29.57%

Castle Biosciences Inc. currently has a PE ratio of -12.10, a price-to-book (PB) ratio of 1.63, a price-to-sale (PS) ratio of 8.19, a price to cashflow ratio of 230.60, a PEG ratio of 2.32, a ROA of -11.71%, a ROC of -12.43% and a ROE of -12.66%. The company’s profit margin is -56.85%, its EBITDA margin is -55.90%, and its revenue ttm is $75.37 Million , which makes it $2.87 revenue per share.

Of the last four earnings reports from Castle Biosciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.57 for the next earnings report. Castle Biosciences Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Castle Biosciences Inc. is Strong Buy (1), with a target price of $46, which is +34.46% compared to the current price. The earnings rating for Castle Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Castle Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Castle Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 15.21, ATR14 : 2.46, CCI20 : 189.96, Chaikin Money Flow : 0.03, MACD : 2.36, Money Flow Index : 67.41, ROC : 25.22, RSI : 58.24, STOCH (14,3) : 83.01, STOCH RSI : 0.98, UO : 51.31, Williams %R : -16.99), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Castle Biosciences Inc. in the last 12-months were: Bernhard E. Spiess (Option Excercise at a value of $0), Daniel M. Bradbury (Option Excercise at a value of $0), Daniel M. Bradbury (Sold 159 080 shares of value $6 922 181 ), Derek J. Maetzold (Option Excercise at a value of $192 079), Derek J. Maetzold (Sold 65 236 shares of value $3 225 601 ), Ellen Goldberg (Option Excercise at a value of $0), Frank Stokes (Option Excercise at a value of $13 520), G. Bradley Cole (Option Excercise at a value of $0), Kimberlee Caple (Option Excercise at a value of $0), Kristen Oelschlager (Option Excercise at a value of $0), Mara Glickman Aspinall (Option Excercise at a value of $0), Miles D. Harrison (Option Excercise at a value of $0), Tobin W. Juvenal (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (100.00 %)
3 (100.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

Castle Biosciences Inc.

Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.

CEO: Derek J. Maetzold

Telephone: +1 866 788-9007

Address: 820 S. Friendswood Drive, Friendswood 77546, TX, US

Number of employees: 135

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

55%45%

Bearish Bullish

48%52%

TipRanks News for CSTL

Wed, 27 Jul 2022 03:30 GMT Castle Biosciences (CSTL) Receives a Buy from Robert W. Baird

- TipRanks. All rights reserved.

Tue, 10 May 2022 12:47 GMT Castle Biosciences (CSTL) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

Thu, 31 Mar 2022 06:57 GMT Castle Biosciences (CSTL) Receives a Buy from Leerink Partners

- TipRanks. All rights reserved.

News

Stocktwits